Alterations in two specific genes may help forecast whether patients will experience significant weight loss when using GLP-1 drugs for obesity treatment. These genetic changes could also indicate the likelihood of side effects such as nausea or vomiting, which are common with these medications.
“I think we have proof of concept here that genetics is playing a role in terms of GLP-1 efficacy and side effects,” stated Adam Auton, a vice president at the 23andMe Research Institute and the lead author of the paper, which was published in Nature on Wednesday.
While external researchers found the results intriguing and impressive, there is some skepticism about the practical impact of these genetic findings on patient care. Nevertheless, individuals using 23andMe’s Total Health platform will gain access to insights about these genes and their implications for GLP-1 use.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
View All Plans
To read the rest of this story subscribe to STAT+.
Subscribe
.
